Insmed Inc

NASDAQ:INSM   3:12:42 PM EDT
36.51
-0.48 (-1.30%)
Products, Regulatory, Other Pre-Announcement

Insmed Says Initiated Phase 1 Study Of Treprostinil Palmitil Inhalation Powder Phase 2A Study In Pulmonary Arterial Hypertension Planned For 2021

Published: 09/30/2020 12:37 GMT
Insmed Inc (INSM) - Insmed - Initiated Phase 1 Study of Treprostinil Palmitil Inhalation Powder; Phase 2a Study in Pulmonary Arterial Hypertension Planned for 2021.
Insmed - Expects to Initiate Registrational Phase 3 Aspen Trial of Brensocatib in Patients With Non-cystic Fibrosis Bronchiectasis in Q4.
Insmed - Expansion Into Additional Neutrophil-mediated Diseases Planned in 2021.
Insmed - Expanding Opportunity for Arikayce With Planned European Launch by 2020 End & Potential Japanese Launch in 2021, If Approved, in Refractory Mac Lung Disease.
Insmed - Cash Runway of Over Three Years Based on Currently Planned Development Programs.
Insmed - Expects to Initiate Registrational Program in Front-line Ntm in 2020.